References
- P. Borst, "Genetic Mechanisms of Drug Resistance: A Review", Acta Oncol., Vol. 30, pp. 87-105, 1991. https://doi.org/10.3109/02841869109091819
- W. T. Bellamy and W. S. Dalton, "Multidrug resistance in the laboratory and clinic", Adv. Clin. Chem., Vol. 31, pp. 2-2, 1994.
- D. W. Loe, R. G. Deeley, and S. P. Cole "Biology of the multidrug resistance-associated protein, MRP", Eur. J. Cancer, Vol. 32A, pp. 945-957, 1996.
- M. Clynes, C. Daly, R. NicAmhlaoibh, D. Cronin, C. Elliott, R. O'Connor, T. O'Doherty, L. Connolly, A. Howlett, and K. Scanlon, "Recent developments in drug resistance and apoptosis research", Crit. Rev. Oncol. Hematol., Vol. 28, pp. 181-205, 1998. https://doi.org/10.1016/S1040-8428(98)00018-3
- S. P. C. Cole and R. G. Deeley, "Multidrug resistance mediated by the ATP-binding cassette transporter protein MRP", Bioessays, Vol. 20, pp. 931-940, 1998. https://doi.org/10.1002/(SICI)1521-1878(199811)20:11<931::AID-BIES8>3.0.CO;2-J
- H. W. V. Veen and W. N. Konings, "Structure and function of multidrug transporters", Adv. Exp. Med. Biol. Vol. 456, pp. 145-158, 1998.
- S. V. Ambudkar, S. Dey, C. A. Hrycyna, M. Ramachandra, I. Pastan, and M. M. Gottesman, "Biochemical, cellular, and pharmacological aspects of the multidrug transporter 1", Annu. Rev. Pharmacol. Toxicol., Vol. 39, pp. 361-398, 1999. https://doi.org/10.1146/annurev.pharmtox.39.1.361
- P. Borst, R. Evers, M. Kool, and J. Wijnholds, "The multidrug resistance protein family", Biochim. Biophys. Acta Biomembr., Vol. 1461, pp. 347-357, 1999. https://doi.org/10.1016/S0005-2736(99)00167-4
- D. R. Hipfner, R. G. Deeley, and S. P. C. Cole, "Structural, mechanistic and clinical aspects of MRP1", Biochim. Biophys. Acta Biomembr., Vol. 1461, pp. 359-376, 1999. https://doi.org/10.1016/S0005-2736(99)00168-6
- J. Konig, A. T. Nies, Y. Cui, I. Leier, and D. Keppler, "Conjugate export pumps of the multidrug resistance protein (MRP) family: localization, substrate specificity, and MRP2-mediated drug resistance", Biochim. Biophys. Acta Biomembr., Vol. 1461, pp. 377-394, 1999. https://doi.org/10.1016/S0005-2736(99)00169-8
- M. M. Gottesman, T. Fojo, and S. E. Bates, "Multidrug resistance in cancer: role of ATP-dependent transporters", Nat. Rev. Cancer, Vol. 2, pp. 48-58, 2002. https://doi.org/10.1038/nrc706
- M. M. Gottesman and I. Pastan, "Biochemistry of multidrug resistance mediated by the multidrug transporter", Annu. Rev. Biochem., Vol. 62, pp. 385-427, 1993. https://doi.org/10.1146/annurev.bi.62.070193.002125
- M. Dean, A. Rzhetsky, and R. Alliknets, "The human ATP binding cassette (ABC) transporter superfamily", Genome Res., Vol. 11, pp. 1156-1166, 2001. https://doi.org/10.1101/gr.GR-1649R
- G. D. Leonard, T. Fojo, and S. E. Bates, "The role of ABC transporters in clinical practice", The Oncologist, Vol. 8, pp. 411-424, 2003. https://doi.org/10.1634/theoncologist.8-5-411
- S. G. Aller, J. Yu, A. Ward, Y. Weng, S. Chittaboina, R. Zhuo, P. M. Harrell, Y. T. Trinh, Q. Zhang, and I. L. Urbatsch, "Structure of P-glycoprotein reveals a molecular basis for poly-specific drug binding", Science, Vol. 323, pp.1718-1722, 2009. https://doi.org/10.1126/science.1168750
- D. Khare, M. L. Oldham, C. Orelle, A. L. Davidson, and J. Chen, "Alternating access in maltose transporter mediated by rigid-body rotations", Mol. cell, Vol. 33, pp. 528-536, 2009. https://doi.org/10.1016/j.molcel.2009.01.035
- K. Dano, "Active outward transport of daunomycin in resistant Ehrlich ascites tumor cells", Biochim. Biophys. Acta, Vol. 323, pp. 466-483, 1973. https://doi.org/10.1016/0005-2736(73)90191-0
- R. L. Juliano and V. Ling, "A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants", Biochim. Biophys. Acta Biomembr., Vol. 455, pp. 152-162, 1976. https://doi.org/10.1016/0005-2736(76)90160-7
- H. Venter, R. A. Shilling, S. Velamakanni, L. Balakrishnan, and H. W. van Veen, "An ABC transporter with a secondary-active multidrug translocator domain", Nature, Vol. 426, pp. 866-870, 2003. https://doi.org/10.1038/nature02173
- T. W. Loo and D. M. Clarke, "The transmembrane domains of the human multidrug resistance P-glycoprotein are sufficient to mediate drug binding and trafficking to the cell surface", J. Biol. Chem., Vol. 274, pp. 24759-24765, 1999. https://doi.org/10.1074/jbc.274.35.24759
- A. B. Shapiro and V. Ling, "Positively Cooperative Sites for Drug Transport by P Glycoprotein with Distinct Drug Specificities", Eur. J. Biochem., Vol. 250, pp. 130-137, 1997. https://doi.org/10.1111/j.1432-1033.1997.00130.x
- A. B. Shapiro, K. Fox, P. Lam, and V. Ling, "Stimulation of P glycoprotein mediated drug transport by prazosin and progesterone", Eur. J. Biochem., Vol. 259, pp. 841-850, 1999.
- C. Martin, G. Berridge, C. F. Higgins, P. Mistry, P. Charlton, and R. Callaghan, "Communication between multiple drug binding sites on P-glycoprotein", Mol. Pharmacol., Vol. 58, pp. 624-632, 2000. https://doi.org/10.1124/mol.58.3.624
- T. W. Loo and D. M. Clarke, "Identification of residues within the drug-binding domain of the human multidrug resistance P-glycoprotein by cysteinescanning mutagenesis and reaction with dibromobimane", J. Biol. Chem., Vol. 275, pp. 39272-39278, 2000. https://doi.org/10.1074/jbc.M007741200
- T. W. Loo and D. M. Clarke, "Defining the drugbinding site in the human multidrug resistance Pglycoprotein using a methanethiosulfonate analog of verapamil, MTS-verapamil", J. Biol. Chem., Vol. 276, pp. 14972-14979, 2001. https://doi.org/10.1074/jbc.M100407200
- T. W. Loo and D. M. Clarke, "Location of the rhodamine-binding site in the human multidrug resistance P-glycoprotein", J. Biol. Chem., Vol. 277, pp. 44332-44338, 2002. https://doi.org/10.1074/jbc.M208433200
- R. J. P. Dawson and K. P. Locher, "Structure of a bacterial multidrug ABC transporter", Nature, Vol. 443, pp. 180-185, 2006. https://doi.org/10.1038/nature05155
- R. J. P. Dawson and K. P. Locher, "Structure of the multidrug ABC transporter Sav1866 from Staphylococcus aureus in complex with AMP-PNP", FEBS letters, Vol. 581, pp. 935-938, 2007. https://doi.org/10.1016/j.febslet.2007.01.073
- C. F. Higgins and K. J. Linton, "The ATP switch model for ABC transporters", Nat. Struct. Mol. Biol., Vol. 11, pp. 918-926, 2004. https://doi.org/10.1038/nsmb836
- Z. E. Sauna and S. V. Ambudkar, "About a switch: how P-glycoprotein (ABCB1) harnesses the energy of ATP binding and hydrolysis to do mechanical work", Mol. Cancer Ther., Vol. 6, pp. 13, 2007.
- T. W. Loo, M. C. Bartlett, and D. M. Clarke, "Simultaneous binding of two different drugs in the binding pocket of the human multidrug resistance P-glycoprotein", J. Biol. Chem., Vol. 278, pp. 39706-39710, 2003. https://doi.org/10.1074/jbc.M308559200
- S. Ayesh, Y. M. Shao, and W. D. Stein, "Co-operative, competitive and non-competitive interactions between modulators of P-glycoprotein", Biochim. Biophys. Acta, Mol. Basis Dis., Vol. 1316, pp. 8-18, 1996. https://doi.org/10.1016/0925-4439(96)00008-7
- T. W. Loo and D. M. Clarke, "Identification of residues in the drug-binding site of human P-glycoprotein using a thiol-reactive substrate", J. Biol. Chem., Vol. 272, pp. 31945-31948, 1997. https://doi.org/10.1074/jbc.272.51.31945
- T. W. Loo, M. C. Bartlett, and D. M. Clarke, "Transmembrane segment 7 of human P-glycoprotein forms part of the drug-binding pocket", Biochem. J., Vol. 399, pp. 351-359, 2006. https://doi.org/10.1042/BJ20060715
- C. H. Choi, "ABC transporters as multidrug resistance mechanisms and the development of chemosensitizers for their reversal", Cancer Cell Int., Vol. 5, pp. 30, 2005. https://doi.org/10.1186/1475-2867-5-30
- M. L. Veigl, T. C. Vanaman, and W. D. Sedwick, "Calcium and calmodulin in cell growth and transformation", Biochim. Biophys. Acta, Vol. 738, pp. 21-48, 1984.
- M. J. Borgnia, G. D. Eytan, and Y. G. Assaraf, "Competition of hydrophobic peptides, cytotoxic drugs, and chemosensitizers on a common P-glycoprotein pharmacophore as revealed by its ATPase activity", J. Biol. Chem., Vol. 271, pp. 3163-3171, 1996. https://doi.org/10.1074/jbc.271.6.3163
- R. Krishna and L. D. Mayer, "Multidrug resistance (MDR) in cancer:: Mechanisms, reversal using modulators of MDR and the role of MDR modulators in influencing the pharmacokinetics of anticancer drugs", Eur. J. Pharm. Sci., Vol. 11, pp. 265-283, 2000. https://doi.org/10.1016/S0928-0987(00)00114-7
- D. R. Ferry, H. Traunecker, and D. J. Kerr, "Clinical trials of P-glycoprotein reversal in solid tumours", Eur. J. Cancer, Vol. 32, pp. 1070-1081, 1996. https://doi.org/10.1016/0959-8049(96)00091-3
- J. M. Ford and W. N. Hait, "Pharmacology of drugs that alter multidrug resistance in cancer", Pharmacol. Rev., Vol. 42, pp. 155-199, 1990.
- J. G. W. Theis, H. S. L. Chan, M. L. Greenberg, D. Malkin, V. Karaskov, I. Moncica, G. Koren, and J. Doyle, "Assessment of systemic toxicity in children receiving chemotherapy with cyclosporine for sarcoma", Med. Pediatr. Oncol., Vol. 34, pp. 242-249, 2000. https://doi.org/10.1002/(SICI)1096-911X(200004)34:4<242::AID-MPO2>3.0.CO;2-U
- P. A. W. Boekhorst, J. Kapel, M. Schoester, and P. Sonneveld, "Reversal of typical multidrug resistance by cyclosporin and its non-immunosuppressive analogue SDZ PSC 833 in Chinese hamster ovary cells expressing themdr1 phenotype", Cancer Chemother. Pharmacol., Vol. 30, pp. 238-242, 1992. https://doi.org/10.1007/BF00686322
- P. R. Twentyman and N. M. Bleehen, "Resistance modification by PSC-833, a novel non-immunosuppressive cyclosporin A", Eur. J. Cancer Clin. Oncol., Vol. 27, pp. 1639-1642, 1991. https://doi.org/10.1016/0277-5379(91)90435-G
- H. Thomas and H. M. Coley, "Overcoming multidrug resistance in cancer: an update on the clinical strategy of inhibiting p-glycoprotein", Cancer Control, Vol. 10, pp. 159-159, 2003. https://doi.org/10.1177/107327480301000207
- B. L. Lum and M. P. Gosland, "MDR expression in normal tissues: pharmacologic implications for the clinical use of P-glycoprotein inhibitors", Hematol. Oncol North Am., Vol. 9, pp. 319-336, 1995.
- C. Wandel, "P-glycoprotein and cytochrome P-450 3A inhibition: dissociation of inhibitory potencies", Cancer Res., Vol. 59, pp. 3944-3948, 1999.
- S. Bates, M. Kang, B. Meadows, S. Bakke, P. Choyke, M. Merino, B. Goldspiel, I. Chico, T. Smith, and C. Chen, "A Phase I study of infusional vinblastine in combination with the p glycoprotein antagonist PSC 833 (valspodar)", Cancer, Vol. 92, pp. 1577-1590, 2001. https://doi.org/10.1002/1097-0142(20010915)92:6<1577::AID-CNCR1484>3.0.CO;2-H
- E. K. Rowinsky, L. Smith, Y. M. Wang, P. Chaturvedi, M. Villalona, E. Campbell, C. Aylesworth, S. G. Eckhardt, L. Hammond, and M. Kraynak, "Phase I and pharmacokinetic study of paclitaxel in combination with biricodar, a novel agent that reverses multidrug resistance conferred by overexpression of both MDR1 and MRP", J. Clin. Oncol., Vol. 16, pp. 2964-2976, 1998. https://doi.org/10.1200/JCO.1998.16.9.2964
-
T. Yanagisawa, A. Newman, H. Coley, J. Renshaw, C. R. Pinkerton, and K. Pritchard-Jones, "BIRICO-DAR (VX-710;
$Incel^{TM}$ ): an effective chemosensitizer in neuroblastoma", Br. J. Cancer, Vol. 80, pp. 1190-1196, 1999. https://doi.org/10.1038/sj.bjc.6990485 - K. D. Bunting, "ABC transporters as phenotypic markers and functional regulators of stem cells", Stem Cells, Vol. 20, pp. 11-20, 2002. https://doi.org/10.1002/stem.200011
- A. H. Dantzig, R. L. Shepard, K. L. Law, L. Tabas, S. Pratt, J. S. Gillespie, S. N. Binkley, M. T. Kuhfeld, J. J. Starling and S. A. Wrighton, "Selectivity of the multidrug resistance modulator, LY335979, for P-glycoprotein and effect on cytochrome P-450 activities", J. Pharmacol. Exp. Ther., Vol. 290, pp. 854-862, 1999.
- C. Wandel, R. B. Kim, S. Kajiji, P. Guengerich, G. R. Wilkinson, and A. J. Wood, "P-Glycoprotein and cytochrome P-450 3A inhibition: Dissociation of inhibitory Potencies", Cancer Res., Vol. 59, pp. 3944-3948, 1999.
- C. Martin, G. Berridge, P. Mistry, C. Higgins, P. Charlton, and R. Callaghan, "The molecular interaction of the high affinity reversal agent XR9576 with P glycoprotein", Br. J. Pharmacol., Vol. 128, pp. 403-411, 1999. https://doi.org/10.1038/sj.bjp.0702807
- A. H. Dantzig, K. L. Law, J. Cao, and J. J. Starling, "Reversal of multidrug resistance by the P-glycoprotein modulator, LY335979, from the bench to the clinic", Curr. Med. Chem., Vol. 8, pp. 39-50, 2001. https://doi.org/10.2174/0929867013373903
- M. Roe, A. Folkes, P. Ashworth, J. Brumwell, L. Chima, S. Hunjan, I. Pretswell, W. Dangerfield, H. Ryder, and P. Charlton, "Reversal of P-glycoprotein mediated multidrug resistance by novel anthranilamide derivatives", Bioorg. Med. Chem. Lett., Vol. 9, pp. 595-600, 1999. https://doi.org/10.1016/S0960-894X(99)00030-X
- C. Martin, G. Berridge, P. Mistry, C. Higgins, P. Charlton, and R. Callaghan, "The molecular interaction of the high affinity reversal agent XR9576 with P glycoprotein", Br. J. Pharmacol., Vol. 128, pp. 403-411, 1999. https://doi.org/10.1038/sj.bjp.0702807
- A. H. Dantzig, R. L. Shepard, J. Cao, K. L. Law, W. J. Ehlhardt, T. M. Baughman, T. F. Bumol, and J. J. Starling, "Reversal of P-glycoprotein-mediated multidrug resistance by a potent cyclopropyldibenzosuberane modulator, LY335979", Cancer Res., Vol. 56, pp. 4171-4179, 1996.
- J. J. Starling, R. L. Shepard, J. Cao, K. L. Law, B. H. Norman, J. S. Kroin, W. J. Ehlhardt, T. M. Baughman, M. A. Winter, and M. G. Bell, "Pharmacological characterization of LY335979: a potent cyclopropyldibenzosuberane modulator of P-glycoprotein", Adv. Enzyme Regul., Vol. 37, pp. 335-347, 1997. https://doi.org/10.1016/S0065-2571(96)00021-0
- A. H. Dantzig, R. L. Shepard, K. L. Law, L. Tabas, S. Pratt, J. S. Gillespie, S. N. Binkley, M. T. Kuhfeld, J. J. Starling and S. A. Wrighton, "Selectivity of the multidrug resistance modulator, LY335979, for P-glycoprotein and effect on cytochrome P-450 activities", J. Pharmacol. Exp. Ther., Vol. 290, pp. 854-862, 1999.
- L. D. Cripe, M. Tallman and C. Karanes, "A phase II trial of zosuquidar (LY335979), a modulator of P-glycoprotein (P-gp) activity, plus daunorubicin and high-dose cytarabine in patients with newly-diagnosed secondary acute myeloid leukemia (AML), refractory anemia with excess blasts in transformation (RAEB-t), or relapsed/refractory AML", Blood, Vol. 98, pp. 595a, 2001.
- S. Tura, F. Morschhauser, P. Zinzani, L. Sloots, M. Burgess and C. Dumontet, "A phase I trial of the P-glycoprotein (Pgp) inhibitor zosuquidar (LY335979) and CHOP chemotherapy in patients with non-Hodgkin's lymphoma", Blood, Vol. 98, pp. 251 2001. https://doi.org/10.1182/blood.V98.1.251
Cited by
- Exploration of the Binding Mode of Indole Derivatives as Potent HIV-1 Inhibitors Using Molecular Docking Simulations vol.6, pp.3, 2011, https://doi.org/10.13160/ricns.2013.6.3.138